- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Paul N. Van de Water Explains the Challenges with Controlling Healthcare Costs and Spending
Paul N. Van de Water, senior fellow, Center on Budget and Policy Priorities, suggests that controlling healthcare costs and spending is a complicated process - one in which no right answer exists.
Paul N. Van de Water, senior fellow, Center on Budget and Policy Priorities, suggests that controlling healthcare costs and spending is a complicated process — one in which no right answer exists. He says that healthcare stakeholders will need to try a number of approaches, with each approach carrying a different trade-off.
“Controlling healthcare costs means lower growth of income for some healthcare providers — it could mean the beneficiaries have to pay more, it could mean the beneficiaries have a more limited choice of providers,” Mr Van de Water says. “We can’t expect to control costs in a painless fashion.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
